|Other names||CPC-10997; Cyoctol; X-Andron|
|By mouth, topical|
|Drug class||Nonsteroidal antiandrogen|
|Chemical and physical data|
|Molar mass||252.398 g·mol−1|
|3D model (JSmol)|
Cioteronel (INN, USAN) (developmental code name CPC-10997; former tentative brand names Cyoctol, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed. It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness) and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.
- Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. p. 570. ISBN 978-0-412-46630-4.
- Lednicer D (21 November 1994). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 11–. ISBN 978-0-471-58959-4.
- Tiwari A, Krishna NS, Nanda K, Chugh A (November 2005). "Benign prostatic hyperplasia: an insight into current investigational medical therapies". Expert Opinion on Investigational Drugs. 14 (11): 1359–72. doi:10.1517/13543722.214.171.1249. PMID 16255676. S2CID 25662071.
- "Cioteronel". Adis Insight. Springer Nature Switzerland AG. Archived from the original on 2016-12-29. Retrieved 2016-11-25.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|
|This dermatologic drug article is a stub. You can help Wikipedia by expanding it.|